Table 2.

Univariate and multivariable analyses of prognostic factors associated with overall survival

Univariate analysis
		HR (95% CI)	p-Value
Age		1.09 (1.04–1.13)	<0.001
	<40 vs. ≥40 years old	7.40 (3.14–17.40)	<0.001
Time since antecedent pregnancy	<48 months vs. ≥48 months	29.31 (9.87–87.04)	<0.001
FIGO stage	II	4.43 (1.06–18.61)	0.042
	III	5.01 (1.68–14.99)	0.004
	IV	11.44 (3.72–35.14)	<0.001
hCG level	(≤4600 vs. >4600)	2.78 (1.25–6.20)	0.010
Mitotic count	(≤4 vs. >4)	3.24 (1.11–9.44)	0.036
Invasion	≤50% >50% myometrial invasion	2.20 (0.24–16.93)	0.513
	Myometrial vs. serosal invasion	3.19 (0.93–10.98)	0.066
	Lympho-vascular invasion	1.91 (0.61–5.99)	0.271
Treatment	Chemotherapy	2.27 (0.90–5.69)	0.080
	Surgery	0.25 (0.10–0.59)	0.002
Multivariable analysis
		HR (95% CI)	p-Value
Age	<40 vs. ≥40 years old	2.83 (0.97–8.28)	0.058
Time since antecedent pregnancy	<48 months vs. ≥48 months	14.57 (4.17–50.96)	<0.001
FIGO stage	II	1.58 (0.31–8.22)	0.587
	III	4.02 (1.05–15.44)	0.043
	IV	6.18 (1.61–23.81)	0.008
hCG level	(≤4600 vs. >4600)	1.20 (0.48–3.04)	0.697
Mitotic count	(≤4 vs. >4)	0.95 (0.26–3.42)	0.938